Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Charl van Zyl | President & CEO | 5.63M | -- | 1967 |
| Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions | 1.3M | -- | 1977 |
| Mr. Lars Bang | Executive Vice President of Product Development & Supply | 1.21M | -- | 1962 |
| Dr. Per Johan Luthman Ph.D. | Executive Vice President of Research & Development | 1.34M | -- | 1959 |
| Dr. Tarek Samad Ph.D. | Senior VP & Head of Research | -- | -- | -- |
| Jens Hoyer | Vice President & Head of Investor Relations | -- | -- | -- |
| Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs | -- | -- | 1975 |
| Ms. Dianne Holto | Executive Vice President of People & Culture | -- | -- | 1973 |
| Mr. Palle Holm Olesen | Chief Specialist & VP of Investor Relations | -- | -- | -- |
| Mr. Bjorn R. Mogensen | Senior Vice President of Group Finance | -- | -- | -- |
H. Lundbeck A/S
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,707
Description
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Corporate Governance
Upcoming Events
May 14, 2025 at 6:30 AM UTC
H. Lundbeck A/S Earnings Date
Recent Events
March 27, 2025 at 12:00 AM UTC
Ex-Dividend Date